<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="517">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>19/10/2005</approvaldate>
  <actrnumber>ACTRN12605000664640</actrnumber>
  <trial_identification>
    <studytitle>Mechanisms of Action of an ATTORI Celery Seed Extract in Osteoarthritis</studytitle>
    <scientifictitle>Mechanisms of Action of an ATTORI Celery Seed Extract in Osteoarthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>400mg per day ATTORI Celery Seed extract versus placebo for 8 weeks</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of coagualation</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of fibrinolysis</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of lipids</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of inflammation</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of cartilage </outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To study actions of an ATTORI celery seed extract on laboratory markers including measures of bone degradation</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the efficacy of an ATTORI Celery Seed Extract for the treatment of Osteoarthritis by performing a randomised clinical trial utilising the Western Ontario and McMasters Universities (WOMAC) OA index for hip and knee OA, a well validated instrument.</outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A Quality of Life questionairre (SF36) will also be included in this assessment. </outcome>
      <timepoint>Baseline measures being taken at weeks -3 and 0 (first arm) and weeks 13 and 16 (second arm) and treatment measures taken at weeks 3 and 6 (first arm) and weeks 19 and 22 (second arm).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of painful OA of the hip or knee, with or without other joint involvement, as defined by:(i) hip or knee pain while standing, walking and/or in motion of at least 3 months duration, and(ii) evidence of one or more of the following features in an X-ray picture: osteophytes, osteosclerosis, cysts or joint space narrowing, and(iii) a WOMAC score not less than 20.Subjects who have given their informed written consent to participate.Subjects willing to discontinue their current OA treatment for the study duration, commencing at least 2 weeks prior to their first visit.  This includes treatment with intra-articular injections, corticosteroids, NSAIDs, non-prescription therapies, chondroprotective agents, occlusive dressings, physiotherapy, or orthopaedic technical measures.Subjects of childbearing age who agree to continue using contraceptive  measures for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe false alignment of the axis of the knee or hip.Surgery on the knee or hip within the past 2 months or arthroscopy within the past 2 months.Administration of intra-articular injections (e.g. corticosteroids, chondroprotective agents) or treatment with any long acting osteoarthritic therapy in the previous 2 months.Participation in another therapeutic trial within the previous 30 days.Infectious or inflammatory diseases.Female subjects who are pregnant or lactating.Subjects who are unwilling to comply with the study requirements including discontinuation of current osteoarthritis treatment.Subjects with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.Subjects with contra-indications to the study medication or to paracetamol.Reliance on the use of lipolytic, fibrinolytic, anti-coagulant or anti-inflammatory agents or agents that influence platelet function (especially aspirin, aspirin containing compounds and other NSAIDs).A history of trauma associated with the affected joints.Subjects with insulin dependent diabetes mellitus.Subjects with known hypersensitivity to celery.Subjects with any bleeding disorder.Subjects with a history of alcohol or substance abuseSubjects with significant gastrointestinal or renal disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes were held until all subjects had and database had been locked</concealment>
    <sequence>Randomisation schedule was provided by Quintiles (study moniters)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>6/06/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>ATTORI</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>The Australian Tea Tree Oil Research Institute Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Greenslopes Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Cross University</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
Mater Health Services
2nd Floor
Community Services Buildings
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax />
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
Mater Health Services
2nd Floor
Community Services Buildings
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406120</phone>
      <fax />
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>